Safety of Tenofovir Gel, a Vaginal Microbicide, in South African Women: Results of the Caprisa 004 Trial | Zendy

David C. Sokal | Zendy; Quarraisha Abdool Karim | Zendy; Sengeziwe Sibeko | Zendy; hlanhla YendeZuma | Zendy; Leila E. Mansoor | Zendy; Cheryl Baxter | Zendy; Anneke Grobler | Zendy; Janet Frolich | Zendy; Ayesha B. M. Kharsany | Zendy; Nomsa Miya | Zendy; Koleka Mlisana | Zendy; Silvia Maarshalk | Zendy; Salim S. Abdool Karim | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Safety of Tenofovir Gel, a Vaginal Microbicide, in South African Women: Results of the Caprisa 004 Trial

Author(s) -

David C. Sokal,

Quarraisha Abdool Karim,

Sengeziwe Sibeko,

hlanhla YendeZuma,

Leila E. Mansoor,

Cheryl Baxter,

Anneke Grobler,

Janet Frolich,

Ayesha B. M. Kharsany,

Nomsa Miya,

Koleka Mlisana,

Silvia Maarshalk,

Salim S. Abdool Karim

Publication year - 2012

Publication title -

antiviral therapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.747

H-Index - 87

eISSN - 2040-2058

pISSN - 1359-6535

DOI - 10.3851/imp2311

Subject(s) - medicine , placebo , microbicide , adverse effect , tenofovir , randomized controlled trial , incidence (geometry) , creatinine , obstetrics , human immunodeficiency virus (hiv) , gynecology , virology , physics , alternative medicine , pathology , optics

Tenofovir gel, used vaginally before and after coitus, reduced women's acquisition of HIV by 39%. This is a safety assessment of tenofovir gel, including renal, bone, gastrointestinal, genital and haematological parameters.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research